Suven Pharmaceuticals Ltd's API and Forumulations facilities complete USFDA inspection successfully

Suven Pharmaceuticals Limited's Active Pharmaceutical Ingredients (API) and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram, Hyderabad, India, have completed the PreApproval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections by the US Food & Drug Administration (US FDA) today. The inspection was conducted from February 12, 2024, to February 23, 2024, and no Form 483 has been issued as a result of the inspection.

Shares of Suven Pharmaceuticals Limited was last trading in BSE at Rs. 663.55 as compared to the previous close of Rs. 665.40. The total number of shares traded during the day was 4608 in over 699 trades.

The stock hit an intraday high of Rs. 668.00 and intraday low of 659.00. The net turnover during the day was Rs. 3060527.00.

Source : Equity Bulls

Keywords

SuvenPharmaceuticals INE03QK01018 API FormulationsFacility USFDA Inspection PAI GMP